See related research by Tuinman *et al.*, <http://ccforum.com/content/15/1/R59>

Tuinman and colleagues report the results of a single-institution study in cardiac surgery patients (*n*= 45), documenting that bronchoalveolar lavage fluid cytokine and coagulation markers were significantly increased in a dose-dependent manner with transfusions \[[@B1]\]. They conclude that transfusion was associated with activation of pulmonary inflammation/coagulation and systemic coagulation derangement.

The data are interesting and provocative, and provide a biologic basis for observational studies that reported an association between red blood cell (RBC) transfusions and increased pulmonary complications, including acute lung injury and acute respiratory distress syndrome \[[@B2],[@B3]\]. Translational research studies like this are needed to move this field forward.

Although increased inflammatory/coagulation markers were identified in the multiple transfusion cohort, no clinically relevant difference in pulmonary function (including the PaO~2~/FiO~2~ratio) was identified \[[@B1]\]. Duration of mechanical ventilation was longer in the multiple transfusion cohort, but all were of less than 1 day duration.

A major study limitation is that the three cohorts were not defined on the basis of RBC transfusions alone, as the multiple transfusion cohort received plasma/platelets in addition to RBC transfusions. This factor significantly confounds the issue, as plasma administration is associated with significantly increased risk for pulmonary complications \[[@B4]-[@B7]\]. In a systematic review/meta-analysis of 37 studies, plasma transfusion was associated with significantly increased acute lung injury risk (odds ratio, 2.92; 95% confidence interval, 1.99 to 4.29) \[[@B8]\].

Most importantly, the effects of anticoagulants, heparin antagonists (for example, protamine) or blood-saving strategies (for example, cell-saver technique) and the degree of intraoperative blood loss and hypoperfusion/shock were not considered. Additional study limitations include the small sample size, and increased EuroSCORE in the multiple transfusion cohort, and an inability to assess age of blood as a variable.

The fundamental question of whether RBC transfusion is safe/effective in cardiac surgery is important, and this current study highlights significant concerns particularly with regard to pulmonary complications. Significant variability in transfusion use in cardiac surgery persists, ranging from 7.8 to 92.8% for RBC transfusion \[[@B9]\]. The Transfusion Requirements in Critical Care trial excluded cardiac surgical patients and patients who received trans-fusions before admission to the ICU \[[@B10]\]. The recent Transfusion Requirements After Cardiac Surgery trial - a single-center prospective, randomized clinical trial with patients (*n*= 502) randomized to a liberal strategy (maintain hematocrit ≥30%) or to a restrictive strategy (maintain hematocrit ≥24%) - reported that for each transfused RBC unit, the risk of respiratory complications increased (odds ratio, 1.27; 95% confidence interval, 1.12 to 1.45; *P*\<0.001) with no difference in 30-day all-cause mortality \[[@B11]\].

To resolve this issue regarding transfusion, a large multicenter, prospective, randomized clinical trial regarding the safety (including pulmonary complications) and efficacy of RBC transfusion in cardiac surgery is needed. The National Heart, Lung, and Blood Institute established a State-of-the-Science Symposium on Transfusion Medicine to identify important clinical trial research issues in this field, and a trial in cardiac surgery was strongly recommended \[[@B12]\].
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